View in EDS

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.

Saved in:
Bibliographic Details
Title: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Authors: Gordon, Kenneth B., Puig, Lluís, Foley, Peter, Mamitaro Ohtsuki, Flack, Mary, Ziqian Geng, Yihua Gu, Valdes, Joaquin M., Thompson, Elizabeth H. Z., Bachelez, Hervé, Strober, Bruce, Lebwohl, Mark, Augustin, Matthias, Blauvelt, Andrew, Poulin, Yves, Papp, Kim A., Sofen, Howard, Ohtsuki, Mamitaro (AUTHOR), Geng, Ziqian (AUTHOR), Gu, Yihua (AUTHOR)
Source: Lancet. 8/25/2018, Vol. 392 Issue 10148, p650-661. 12p. 4 Charts, 4 Graphs.
Subjects: Psoriasis treatment, Monoclonal antibodies, Interleukin-23, Cytokines, Placebos, Therapeutic use of immunoglobulins, Subcutaneous injections, Comparative studies, Dermatologic agents, Interleukins, Research methodology, Medical cooperation, Psoriasis, Research, Statistical sampling, Tumor necrosis factors, Evaluation research, Randomized controlled trials, Treatment effectiveness, Blind experiment, Severity of illness index, Pharmacodynamics
Abstract: Background: Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We aimed to assess the efficacy and safety of risankizumab compared with placebo or ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.Methods: UltIMMa-1 and UltIMMa-2 were replicate phase 3, randomised, double-blind, placebo-controlled and active comparator-controlled trials done at 139 sites in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Japan, Mexico, Poland, Portugal, South Korea, Spain, and the USA. Eligible patients were 18 years or older, with moderate-to-severe chronic plaque psoriasis. In each study, patients were stratified by weight and previous exposure to tumour necrosis factor inhibitor and randomly assigned (3:1:1) by use of interactive response technology to receive 150 mg risankizumab, 45 mg or 90 mg ustekinumab (weight-based per label), or placebo. Following the 16-week double-blind treatment period (part A), patients initially assigned to placebo switched to 150 mg risankizumab at week 16; other patients continued their originally randomised treatment (part B, double-blind, weeks 16-52). Study drug was administered subcutaneously at weeks 0 and 4 during part A and at weeks 16, 28, and 40 during part B. Co-primary endpoints were proportions of patients achieving a 90% improvement in the Psoriasis Area Severity Index (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 16 (non-responder imputation). All efficacy analyses were done in the intention-to-treat population. These trials are registered with ClinicalTrials.gov, numbers NCT02684370 (UltIMMa-1) and NCT02684357 (UltIMMa-2), and have been completed.Findings: Between Feb 24, 2016, and Aug 31, 2016, 506 patients in UltIMMa-1 were randomly assigned to receive 150 mg risankizumab (n=304), 45 mg or 90 mg ustekinumab (n=100), or placebo (n=102). Between March 1, 2016, and Aug 30, 2016, 491 patients in UltIMMa-2 were randomly assigned to receive 150 mg risankizumab (n=294), 45 mg or 90 mg ustekinumab (n=99), or placebo (n=98). Co-primary endpoints were met for both studies. At week 16 of UltIMMa-1, PASI 90 was achieved by 229 (75·3%) patients receiving risankizumab versus five (4·9%) receiving placebo (placebo-adjusted difference 70·3% [95% CI 64·0-76·7]) and 42 (42·0%) receiving ustekinumab (ustekinumab-adjusted difference 33·5% [22·7-44·3]; p<0·0001 vs placebo and ustekinumab). At week 16 of UltIMMa-2, PASI 90 was achieved by 220 (74·8%) patients receiving risankizumab versus two (2·0%) receiving placebo (placebo-adjusted difference 72·5% [95% CI 66·8-78·2]) and 47 (47·5%) receiving ustekinumab (ustekinumab-adjusted difference 27·6% [16·7-38·5]; p<0·0001 vs placebo and ustekinumab). In UltIMMa-1, sPGA 0 or 1 at week 16 was achieved by 267 (87·8%) patients receiving risankizumab versus eight (7·8%) receiving placebo (placebo-adjusted difference 79·9% [95% CI 73·5-86·3]) and 63 (63·0%) receiving ustekinumab (ustekinumab-adjusted difference 25·1% [15·2-35·0]; p<0·0001 vs placebo and ustekinumab). In UltIMMa-2, 246 (83·7%) patients receiving risankizumab versus five (5·1%) receiving placebo (placebo-adjusted difference 78·5% [95% CI 72·4-84·5]) and 61 (61·6%) receiving ustekinumab achieved sPGA 0 or 1 at week 16 (ustekinumab-adjusted difference 22·3% [12·0-32·5]; p<0·0001 vs placebo and ustekinumab). The frequency of treatment-emergent adverse events in UltIMMa-1 and UltIMMa-2 was similar across risankizumab (part A: 151 [49·7%] of 304 and 134 [45·6%] of 294; part B: 182 [61·3%] of 297 and 162 [55·7%] of 291), placebo (part A: 52 [51·0%] of 102 and 45 [45·9%] of 98), ustekinumab (part A: 50 [50·0%] of 100 and 53 [53·5%] of 99; part B: 66 [66·7%] of 99 and 70 [74·5%] of 94), and placebo to risankizumab (part B: 65 [67·0%] of 97 and 61 [64·9%] of 94) treatment groups throughout the study duration.Interpretation: Risankizumab showed superior efficacy to both placebo and ustekinumab in the treatment of moderate-to-severe plaque psoriasis. Treatment-emergent adverse event profiles were similar across treatment groups and there were no unexpected safety findings.Funding: AbbVie and Boehringer Ingelheim. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 131524446
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gordon%2C+Kenneth+B%2E%22&quot;&gt;Gordon, Kenneth B.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Puig%2C+Llu&#237;s%22&quot;&gt;Puig, Llu&#237;s&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Foley%2C+Peter%22&quot;&gt;Foley, Peter&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mamitaro+Ohtsuki%22&quot;&gt;Mamitaro Ohtsuki&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Flack%2C+Mary%22&quot;&gt;Flack, Mary&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ziqian+Geng%22&quot;&gt;Ziqian Geng&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yihua+Gu%22&quot;&gt;Yihua Gu&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Valdes%2C+Joaquin+M%2E%22&quot;&gt;Valdes, Joaquin M.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Thompson%2C+Elizabeth+H%2E+Z%2E%22&quot;&gt;Thompson, Elizabeth H. Z.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bachelez%2C+Herv&#233;%22&quot;&gt;Bachelez, Herv&#233;&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Strober%2C+Bruce%22&quot;&gt;Strober, Bruce&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lebwohl%2C+Mark%22&quot;&gt;Lebwohl, Mark&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Augustin%2C+Matthias%22&quot;&gt;Augustin, Matthias&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Blauvelt%2C+Andrew%22&quot;&gt;Blauvelt, Andrew&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Poulin%2C+Yves%22&quot;&gt;Poulin, Yves&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Papp%2C+Kim+A%2E%22&quot;&gt;Papp, Kim A.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sofen%2C+Howard%22&quot;&gt;Sofen, Howard&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ohtsuki%2C+Mamitaro%22&quot;&gt;Ohtsuki, Mamitaro&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Geng%2C+Ziqian%22&quot;&gt;Geng, Ziqian&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gu%2C+Yihua%22&quot;&gt;Gu, Yihua&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 8/25/2018, Vol. 392 Issue 10148, p650-661. 12p. 4 Charts, 4 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psoriasis+treatment%22&quot;&gt;Psoriasis treatment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Monoclonal+antibodies%22&quot;&gt;Monoclonal antibodies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Interleukin-23%22&quot;&gt;Interleukin-23&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cytokines%22&quot;&gt;Cytokines&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Placebos%22&quot;&gt;Placebos&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Therapeutic+use+of+immunoglobulins%22&quot;&gt;Therapeutic use of immunoglobulins&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Subcutaneous+injections%22&quot;&gt;Subcutaneous injections&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Comparative+studies%22&quot;&gt;Comparative studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Dermatologic+agents%22&quot;&gt;Dermatologic agents&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Interleukins%22&quot;&gt;Interleukins&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research+methodology%22&quot;&gt;Research methodology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medical+cooperation%22&quot;&gt;Medical cooperation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psoriasis%22&quot;&gt;Psoriasis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research%22&quot;&gt;Research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Statistical+sampling%22&quot;&gt;Statistical sampling&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Tumor+necrosis+factors%22&quot;&gt;Tumor necrosis factors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Evaluation+research%22&quot;&gt;Evaluation research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Randomized+controlled+trials%22&quot;&gt;Randomized controlled trials&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Treatment+effectiveness%22&quot;&gt;Treatment effectiveness&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Blind+experiment%22&quot;&gt;Blind experiment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Severity+of+illness+index%22&quot;&gt;Severity of illness index&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Pharmacodynamics%22&quot;&gt;Pharmacodynamics&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: &lt;bold&gt;Background: &lt;/bold&gt;Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We aimed to assess the efficacy and safety of risankizumab compared with placebo or ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.&lt;bold&gt;Methods: &lt;/bold&gt;UltIMMa-1 and UltIMMa-2 were replicate phase 3, randomised, double-blind, placebo-controlled and active comparator-controlled trials done at 139 sites in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Japan, Mexico, Poland, Portugal, South Korea, Spain, and the USA. Eligible patients were 18 years or older, with moderate-to-severe chronic plaque psoriasis. In each study, patients were stratified by weight and previous exposure to tumour necrosis factor inhibitor and randomly assigned (3:1:1) by use of interactive response technology to receive 150 mg risankizumab, 45 mg or 90 mg ustekinumab (weight-based per label), or placebo. Following the 16-week double-blind treatment period (part A), patients initially assigned to placebo switched to 150 mg risankizumab at week 16; other patients continued their originally randomised treatment (part B, double-blind, weeks 16-52). Study drug was administered subcutaneously at weeks 0 and 4 during part A and at weeks 16, 28, and 40 during part B. Co-primary endpoints were proportions of patients achieving a 90% improvement in the Psoriasis Area Severity Index (PASI 90) and a static Physician&#39;s Global Assessment (sPGA) score of 0 or 1 at week 16 (non-responder imputation). All efficacy analyses were done in the intention-to-treat population. These trials are registered with ClinicalTrials.gov, numbers NCT02684370 (UltIMMa-1) and NCT02684357 (UltIMMa-2), and have been completed.&lt;bold&gt;Findings: &lt;/bold&gt;Between Feb 24, 2016, and Aug 31, 2016, 506 patients in UltIMMa-1 were randomly assigned to receive 150 mg risankizumab (n=304), 45 mg or 90 mg ustekinumab (n=100), or placebo (n=102). Between March 1, 2016, and Aug 30, 2016, 491 patients in UltIMMa-2 were randomly assigned to receive 150 mg risankizumab (n=294), 45 mg or 90 mg ustekinumab (n=99), or placebo (n=98). Co-primary endpoints were met for both studies. At week 16 of UltIMMa-1, PASI 90 was achieved by 229 (75&#183;3%) patients receiving risankizumab versus five (4&#183;9%) receiving placebo (placebo-adjusted difference 70&#183;3% [95% CI 64&#183;0-76&#183;7]) and 42 (42&#183;0%) receiving ustekinumab (ustekinumab-adjusted difference 33&#183;5% [22&#183;7-44&#183;3]; p&lt;0&#183;0001 vs placebo and ustekinumab). At week 16 of UltIMMa-2, PASI 90 was achieved by 220 (74&#183;8%) patients receiving risankizumab versus two (2&#183;0%) receiving placebo (placebo-adjusted difference 72&#183;5% [95% CI 66&#183;8-78&#183;2]) and 47 (47&#183;5%) receiving ustekinumab (ustekinumab-adjusted difference 27&#183;6% [16&#183;7-38&#183;5]; p&lt;0&#183;0001 vs placebo and ustekinumab). In UltIMMa-1, sPGA 0 or 1 at week 16 was achieved by 267 (87&#183;8%) patients receiving risankizumab versus eight (7&#183;8%) receiving placebo (placebo-adjusted difference 79&#183;9% [95% CI 73&#183;5-86&#183;3]) and 63 (63&#183;0%) receiving ustekinumab (ustekinumab-adjusted difference 25&#183;1% [15&#183;2-35&#183;0]; p&lt;0&#183;0001 vs placebo and ustekinumab). In UltIMMa-2, 246 (83&#183;7%) patients receiving risankizumab versus five (5&#183;1%) receiving placebo (placebo-adjusted difference 78&#183;5% [95% CI 72&#183;4-84&#183;5]) and 61 (61&#183;6%) receiving ustekinumab achieved sPGA 0 or 1 at week 16 (ustekinumab-adjusted difference 22&#183;3% [12&#183;0-32&#183;5]; p&lt;0&#183;0001 vs placebo and ustekinumab). The frequency of treatment-emergent adverse events in UltIMMa-1 and UltIMMa-2 was similar across risankizumab (part A: 151 [49&#183;7%] of 304 and 134 [45&#183;6%] of 294; part B: 182 [61&#183;3%] of 297 and 162 [55&#183;7%] of 291), placebo (part A: 52 [51&#183;0%] of 102 and 45 [45&#183;9%] of 98), ustekinumab (part A: 50 [50&#183;0%] of 100 and 53 [53&#183;5%] of 99; part B: 66 [66&#183;7%] of 99 and 70 [74&#183;5%] of 94), and placebo to risankizumab (part B: 65 [67&#183;0%] of 97 and 61 [64&#183;9%] of 94) treatment groups throughout the study duration.&lt;bold&gt;Interpretation: &lt;/bold&gt;Risankizumab showed superior efficacy to both placebo and ustekinumab in the treatment of moderate-to-severe plaque psoriasis. Treatment-emergent adverse event profiles were similar across treatment groups and there were no unexpected safety findings.&lt;bold&gt;Funding: &lt;/bold&gt;AbbVie and Boehringer Ingelheim. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=131524446
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(18)31713-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 650
    Subjects:
      – SubjectFull: Psoriasis treatment
        Type: general
      – SubjectFull: Monoclonal antibodies
        Type: general
      – SubjectFull: Interleukin-23
        Type: general
      – SubjectFull: Cytokines
        Type: general
      – SubjectFull: Placebos
        Type: general
      – SubjectFull: Therapeutic use of immunoglobulins
        Type: general
      – SubjectFull: Subcutaneous injections
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Dermatologic agents
        Type: general
      – SubjectFull: Interleukins
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Psoriasis
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Statistical sampling
        Type: general
      – SubjectFull: Tumor necrosis factors
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Severity of illness index
        Type: general
      – SubjectFull: Pharmacodynamics
        Type: general
    Titles:
      – TitleFull: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gordon, Kenneth B.
      – PersonEntity:
          Name:
            NameFull: Puig, Lluís
      – PersonEntity:
          Name:
            NameFull: Foley, Peter
      – PersonEntity:
          Name:
            NameFull: Mamitaro Ohtsuki
      – PersonEntity:
          Name:
            NameFull: Flack, Mary
      – PersonEntity:
          Name:
            NameFull: Ziqian Geng
      – PersonEntity:
          Name:
            NameFull: Yihua Gu
      – PersonEntity:
          Name:
            NameFull: Valdes, Joaquin M.
      – PersonEntity:
          Name:
            NameFull: Thompson, Elizabeth H. Z.
      – PersonEntity:
          Name:
            NameFull: Bachelez, Hervé
      – PersonEntity:
          Name:
            NameFull: Strober, Bruce
      – PersonEntity:
          Name:
            NameFull: Lebwohl, Mark
      – PersonEntity:
          Name:
            NameFull: Augustin, Matthias
      – PersonEntity:
          Name:
            NameFull: Blauvelt, Andrew
      – PersonEntity:
          Name:
            NameFull: Poulin, Yves
      – PersonEntity:
          Name:
            NameFull: Papp, Kim A.
      – PersonEntity:
          Name:
            NameFull: Sofen, Howard
      – PersonEntity:
          Name:
            NameFull: Ohtsuki, Mamitaro
      – PersonEntity:
          Name:
            NameFull: Geng, Ziqian
      – PersonEntity:
          Name:
            NameFull: Gu, Yihua
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 08
              Text: 8/25/2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 392
            – Type: issue
              Value: 10148
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1